Workflow
GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine
GRI BioGRI Bio(US:GRI) Newsfilterยท2024-07-02 13:05

Compared to controls, mice treated with GRI-0621 showed histological improvement in fibrotic lesion in the lung; Inhibition of iNKT activity led to a decrease in fibrosis score and total lung inflammation LA JOLLA, CA, July 02, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the publication o ...